FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2022/03/040798 [Registered on: 04/03/2022] Trial Registered Prospectively
Last Modified On: 02/03/2022
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Effect of Panchgavya Ghrita Nasya and Shankhapuspi kwatha dhara in Chittodvega (Anxiety) 
Scientific Title of Study   A COMPARATIVE STUDY OF PANCHAGAVYA GHRITA NASYA AND SHANKHAPUSPI KWATHA DHARA IN THE MANAGEMENT OF CHITTODVEGA W.S.R. ANXIETY 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ravi Sharma 
Designation  PG Scholar 
Affiliation  V.Y.D.S.Ayurveda mahavidyalaya, khurja 
Address  OPD NO 19 PG Department of Panchkarma V Y D S A M Khurja

Bulandshahar
UTTAR PRADESH
203131
India 
Phone  8824606006  
Fax    
Email  ravisharma78622@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Girish Narain Rai 
Designation  M.D. and HOD 
Affiliation  V.Y.D.S.Ayurveda mahavidyalaya, khurja 
Address  OPD NO 19 PG Department of Panchkarma V Y D S A M Khurja

Bulandshahar
UTTAR PRADESH
203131
India 
Phone  9417448850  
Fax    
Email  girishnarainrai@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Ravi Sharma 
Designation  PG Scholar 
Affiliation  V.Y.D.S.Ayurveda mahavidyalaya, khurja 
Address  OPD NO 19 PG Department of Panchkarma V Y D S A M Khurja

Bulandshahar
UTTAR PRADESH
203131
India 
Phone  8824606006  
Fax    
Email  ravisharma78622@gmail.com  
 
Source of Monetary or Material Support  
Pandit Pyarelal Ramdutt Vaidya Chikitsalaya Dharapa, Khurja Bulandshahr (UP) 
 
Primary Sponsor  
Name  Vaidya Yagya Dutt Sharma Ayurved mahavidyalya 
Address  Dharpa Khurja Bulandshahr Road Khurja Uttar Pradesh 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ravi Sharma  vaidya yagya dutt sharma ayurved mahavidyalya  OPD no. 19 department of Panchkarma vaidya yagya dutt sharma ayurved mahavidyalaya dharpa khurja bulandshahr road khurja utter pradesh
Bulandshahar
UTTAR PRADESH 
8824606006

ravisharma78622@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Vaidya Yagya Dutt Sharma Ayurved Mahavidyalaya Ethical Committee, Khurja  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:F411||Generalized anxiety disorder. Ayurveda Condition: CHITTODVEGA,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmProcedure-nasyam/ nastam, नस्यम्/ नस्तम् (Procedure Reference: CHARAK SAMHITA, SHUSHRUTA SAMHITA, Procedure details: 8 BINDU OF PANCHAGAVYA GHRITA IN ACH NOSTRIL WILL BE ADMINISTERED DAILY IN THE MORNING)
(1) Medicine Name: PANCHAGAVYA GHRITA, Reference: CHARAK SAMHITA, Route: Nasal, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 8(drops), Frequency: od, Duration: 15 Days
2Comparator ArmProcedure-SHIRO DHARA (Procedure Reference: ACHARYA KASTURE, Procedure details: SHIRODHARA FOR 30 MINUTES DAILY IN THE MORNING)
(1) Medicine Name: SHANKHAPUSPI KWATHA, Reference: CHARAK SAMHITA, Route: Topical, Dosage Form: Kwatha/Kashaya, Dose: 1500(ml), Frequency: od, Duration: 15 Days
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  Patients fulfilling the DSM IV-TR diagnostic criteria for anxiety
patients who score at least 14 on the hamilton anxiety rating scale 
 
ExclusionCriteria 
Details  a)patients with alcohol dependency or drug dependency were excluded from the study
b)patients having a chronic illness like asthma malignancies liver cirrhosis chronic renal failure diabetes
c)patients with an acute illness like CVA CCF MI COPD meningitis acute pain conditions and similar other disorders 
 
Method of Generating Random Sequence   Adaptive randomization, such as minimization 
Method of Concealment   An Open list of random numbers 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
none
mild
moderate
severe
severe grossly disabling 
15 days 
 
Secondary Outcome  
Outcome  TimePoints 
none
mild
moderate
severe
severe grossly disabling 
30 days 
 
Target Sample Size   Total Sample Size="30"
Sample Size from India="30" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   10/03/2022 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   in this trial, we are selecting the patients of chittodvega (anxiety), in which we will do the intervention in two groups( 15 patients in each groups),
group I - 15 patients 8 bindu of panchagavya ghrita in each nostril will be administered for 15 days daily in the morning followed by a gap 7 days than again same process will be repeated for 15 days.
group II - 15 patients will be treated with shankhapuspi kwatha sirodhara for 30 minutes daily in the morning for 15 days with the gap of 7 days again same process will be repeated for 15 days.
assessments should be done on the basis of primery and secondry outcome pre and post treatment, as discussed earlier.
 
Close